Physician profile
Albert Mosqueda
NPI 1952302135
$10,458.98
in general payments reported to CMS, 2019-2025
52 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,746 · 2020: $920 · 2021: $1,532 · 2022: $2,045 · 2023: $2,307 · 2024: $789 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,683.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,407.22 | 2019-2025 | |
| Amgen INC. | $1,043.06 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $946.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $748.09 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Daiichi Sankyo INC. | $594.00 | 2019-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $482.46 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $371.41 | 2019-2023 | Steglatro, Belsomra, Steglujan |
| Astellas Pharma US INC | $330.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.96 | 2019-2024 | Ofev, Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $266.57 | 2020-2025 | Shingrix, Arexvy, Penmenvy |
| Pfizer INC. | $260.17 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.65 | 2021-2022 | |
| Esperion Therapeutics, INC. | $180.24 | 2020-2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $133.31 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Mosqueda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.